Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and tocilizumab. Objective: Aim of this study...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2020-09-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2140 |